Ironwood Pharmaceuticals Inc (IRWD) Stock Analysis

Sector: HEALTHCARE - DRUG MANUFACTURERS - SPECIALTY & GENERIC

Exchange: NASDAQ

Key Metrics

• Price: $3.66
• Market Cap: $546.60M
• P/E Ratio: 18.67
• EPS: $0.18
• 52-Week High: $5.78
• 52-Week Low: $0.53

About Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals, Inc. is a leading biotechnology company based in Boston, Massachusetts, focused on developing and commercializing innovative gastrointestinal therapies. With a robust pipeline and a strong commitment to addressing unmet medical needs in the GI sector, the company has established a significant market presence, particularly with its flagship product, Linzess (linaclotide). Ironwood's strategic focus on research and collaboration not only enhances its therapeutic portfo...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Ironwood Pharmaceuticals Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does IRWD pay dividends?

Ironwood Pharmaceuticals Inc (IRWD) does not currently pay a regular dividend.

What is IRWD's P/E ratio?

Ironwood Pharmaceuticals Inc has a price-to-earnings (P/E) ratio of 18.67.

What is IRWD's market cap?

Ironwood Pharmaceuticals Inc (IRWD) has a market capitalization of $546.60M with a current stock price of $3.66.